Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

CRISPR01:59

CRISPR

53.7K
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
53.7K
CRISPR/Cas9 Genome Editing01:28

CRISPR/Cas9 Genome Editing

746
The CRISPR-Cas system serves as a bacterial defense mechanism against invading genetic elements such as viruses and plasmids, forming the foundation for its adaptation as a powerful genome-editing tool. Originally discovered in prokaryotes, this system has been repurposed to revolutionize genetic engineering across a wide range of organisms, including plants, animals, and humans. The core component, Cas9, is an endonuclease derived from Streptococcus pyogenes, capable of introducing...
746

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quinic and Ferulic Acid-Loaded Chitosan Nanoparticles Attenuate Experimental Ulcerative Colitis by Modulating the IL-32/IL-33/IL-34 Axis and NF-κB Signaling.

International journal of inflammation·2026
Same author

Retraction Note: Hurdles to breakthrough in CAR T cell therapy of solid tumors.

Stem cell research & therapy·2026
Same author

A novel combination for in vivo breast cancer treatment: TAK1 inhibition combined with metformin and Lentinula edodes compounds synergistically reinvigorates CD8<sup>+</sup> T Cells.

Journal of translational medicine·2026
Same author

The silymarin and quercetin-loaded pH-sensitive chitosan-tripolyphosphate/Eudragit® S100 nanoparticles improve acetic acid-induced colonic inflammation in rats by modulating Th1 cells, inflammatory cytokines, and oxidative stress.

European journal of pharmacology·2026
Same author

Retraction of "3D Protein-Based Bilayer Artificial Skin for the Guided Scarless Healing of Third-Degree Burn Wounds in Vivo".

Biomacromolecules·2026
Same author

Chitosan-tripolyphosphate/Eudragit® S100 nanoparticles containing quinic acid and ferulic acid ameliorate ulcerative colitis in rats via modulating Th17 cells and pro-inflammatory cytokines.

International journal of biological macromolecules·2025

Related Experiment Video

Updated: Oct 29, 2025

Production of Human CRISPR-Engineered CAR-T Cells
06:33

Production of Human CRISPR-Engineered CAR-T Cells

Published on: March 15, 2021

13.6K

Strengthening the CAR-T cell therapeutic application using CRISPR/Cas9 technology.

Muhammad Sadeqi Nezhad1, Mahboubeh Yazdanifar2, Meghdad Abdollahpour-Alitappeh3

  • 1Department of Clinical Laboratory Science, Young Researchers and Elites Club, Gorgan Branch, Islamic Azad University, Gorgan, Iran.

Biotechnology and Bioengineering
|July 9, 2021
PubMed
Summary

Chimeric antigen receptor T (CAR-T) cell therapy shows promise for aggressive cancers. Gene editing with CRISPR/Cas9 technology can enhance CAR-T cell efficacy and reduce toxicities, paving the way for improved cancer immunotherapy.

Keywords:
CAR-T cellCRISPR/Cas9cancersimmunotherapytherapeutic

More Related Videos

Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells
07:56

Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells

Published on: July 22, 2019

11.6K
Performing an In Vitro Genome-Wide CRISPR Knockout Screen in Chimeric Antigen Receptor T Cells
07:37

Performing an In Vitro Genome-Wide CRISPR Knockout Screen in Chimeric Antigen Receptor T Cells

Published on: January 31, 2025

1.2K

Related Experiment Videos

Last Updated: Oct 29, 2025

Production of Human CRISPR-Engineered CAR-T Cells
06:33

Production of Human CRISPR-Engineered CAR-T Cells

Published on: March 15, 2021

13.6K
Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells
07:56

Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells

Published on: July 22, 2019

11.6K
Performing an In Vitro Genome-Wide CRISPR Knockout Screen in Chimeric Antigen Receptor T Cells
07:37

Performing an In Vitro Genome-Wide CRISPR Knockout Screen in Chimeric Antigen Receptor T Cells

Published on: January 31, 2025

1.2K

Area of Science:

  • Immunotherapy
  • Gene Editing
  • Oncology

Background:

  • Chimeric antigen receptor T (CAR-T) cell therapy is a revolutionary treatment for hematologic malignancies and solid tumors.
  • Five CAR-T therapies are FDA-approved for hematologic malignancies, demonstrating significant clinical success.
  • CAR-T therapy faces challenges including side effects, toxicities, and limitations in efficacy.

Purpose of the Study:

  • To explore the potential of CRISPR/Cas9 gene-editing technology to overcome current CAR-T therapy hurdles.
  • To discuss the application of CRISPR/Cas9 in enhancing CAR-T cell antitumor function and persistence.
  • To address challenges associated with CRISPR/Cas9 accuracy, efficiency, safety, and delivery in CAR-T cell engineering.

Main Methods:

  • Review of CRISPR/Cas9 applications in modifying CAR-T cells.
  • Discussion of strategies to enhance CAR-T cell antitumor activity and persistence using CRISPR/Cas9.
  • Analysis of CRISPR/Cas9-related challenges in CAR-T cell therapy.

Main Results:

  • CRISPR/Cas9 technology can be utilized to modify CAR expression and cellular pathways for improved CAR-T cell performance.
  • Gene editing can enhance CAR-T cell persistence in immunosuppressive tumor microenvironments.
  • CRISPR/Cas9 offers potential for reducing CAR-T cell-associated toxicities and side effects.

Conclusions:

  • The combination of CRISPR/Cas9 and CAR-T cell technology presents a significant opportunity to advance cancer immunotherapy.
  • Addressing the practical challenges of CRISPR/Cas9 is crucial for its successful integration into CAR-T cell therapy.
  • This synergistic approach promises novel therapeutic options for various cancer types.